Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Johnson & Johnson Reports 2018 Third-Quarter Results:

      2018 Third-Quarter Sales of $20.3 Billion Increased 3.6% versus 2017

      2018 Third-Quarter EPS was $1.44

      2018 Adjusted Third-Quarter EPS of $2.05 increased 7.9%*

      Strong Operational Sales and Adjusted EPS Growth*

      Company Increased Sales and EPS Guidance

      (PRNewsfoto/Johnson & Johnson)

      News provided by

      Johnson & Johnson

      Oct 16, 2018, 06:40 ET

      Share this article

      Share this article


      NEW BRUNSWICK, N.J., Oct. 16, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $20.3 billion for the third quarter of 2018, an increase of 3.6% as compared to the third quarter of 2017. Operational sales results increased 5.5%, partially offset by the negative impact of currency of 1.9%. Domestic sales increased 3.6%. International sales increased 3.5%, reflecting operational growth of 7.5% and a negative currency impact of 4.0%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 6.1%, domestic sales increased 3.9% and international sales increased 8.5%.*

      Net earnings and diluted earnings per share for the third quarter of 2018 were $3.9 billion and $1.44, respectively. Third-quarter 2018 net earnings included after-tax intangible amortization expense of approximately $1.0 billion and a net charge for after-tax special items of approximately $0.7 billion, primarily consisting of a non-cash charge attributed to a partial write-down of an in-process research and development asset associated with the acquisition of Alios BioPharma Inc. Third-quarter 2017 net earnings included after-tax intangible amortization expense of approximately $0.9 billion and a charge for after-tax special items of approximately $0.5 billion. Excluding after-tax intangible amortization expense and special items, adjusted net earnings for the current quarter were $5.6 billion and adjusted diluted earnings per share were $2.05, representing increases of 7.3% and 7.9%, respectively, as compared to the same period in 2017.* On an operational basis, adjusted diluted earnings per share also increased 9.5%.* A reconciliation of non-GAAP financial measures is included as an accompanying schedule.

      "We are pleased with our strong third-quarter performance, which reflects continued above-market growth in our Pharmaceutical business, accelerating sales momentum in our Consumer business and consistent progress in our Medical Devices business," said Alex Gorsky, Chairman and Chief Executive Officer. "I'm confident that with our collaborative and inspired J&J colleagues around the world, unique broad-based business model and strategic investments in innovation, we are well positioned for success today and into the future."

      The Company issued sales guidance for the full-year 2018 in a range of $81.0 to $81.4 billion. This reflects an increase in expected operational growth to a range of 5.5% to 6.0%, partially offset by the estimated lower favorable impact of currency. Additionally, the Company increased its adjusted earnings guidance for full-year 2018 to a range of $8.13 to $8.18 per share. This reflects an increase in expected operational EPS growth to a range of 9.3% to 10.0%.

      Segment Sales Performance
      Worldwide Consumer sales of $3.4 billion for the third quarter 2018 represented an increase of 1.8% versus the prior year, consisting of an operational increase of 4.9% and a negative impact from currency of 3.1%. Domestic sales increased 6.6%, while international sales decreased 1.3%, which reflected an operational increase of 3.7% and a negative currency impact of 5.0%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 6.1%, with domestic sales increasing 6.4% and international sales increasing 5.9%.*

      Worldwide operational results, excluding the net impact of acquisitions and divestitures, were driven by over-the-counter products including MOTRIN and TYLENOL analgesics, ZYRTEC upper respiratory and IMODIUM digestive health products; beauty products including NEUTROGENA, OGX and DR. CI LABO; as well as domestic sales of JOHNSON's baby care products.

      During the quarter, the acquisition of Zarbee's, Inc., a leader in naturally-based healthcare products, was completed.

      Worldwide Pharmaceutical sales of $10.3 billion for the third quarter 2018 represented an increase of 6.7% versus the prior year with an operational increase of 8.2% and a negative impact from currency of 1.5%. Domestic sales increased 4.8%, international sales increased 9.5%, which reflected an operational increase of 13.2% and a negative currency impact of 3.7%.  Acquisitions and divestitures had a negligible impact to sales growth in the quarter.

      Worldwide operational results, excluding the net impact of acquisitions and divestitures, were driven by ZYTIGA (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer, IMBRUVICA (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer, STELARA (ustekinumab), a biologic for the treatment of  a number of immune-mediated inflammatory diseases, DARZALEX (daratumumab), for the treatment of multiple myeloma, TREMFYA (guselkumab), for the treatment of adults living with moderate to severe plaque psoriasis, INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults, SIMPONI/SIMPONI ARIA (golimumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases, OPSUMIT (macitentan), an oral endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension to delay disease progression, and UPTRAVI (selexipag), an oral prostacyclin receptor agonist used to treat pulmonary arterial hypertension and reduce hospitalization.

      During the quarter, the U.S. Food and Drug Administration (FDA) approved an additional indication for IMBRUVICA (ibrutinib) in combination with rituximab as a non-chemotherapy combination regimen for patients with Waldenström's Macroglobulinemia, a rare blood cancer. The European Commission (EC) granted marketing authorization for DARZALEX (daratumumab) in combination with VELCADE (bortezomib), a proteasome inhibitor, melphalan, an alkylating agent, and prednisone for the treatment of newly diagnosed multiple myeloma patients who are ineligible for autologous stem cell transplant.  In addition, the FDA approved and the EC granted marketing authorization for SYMTUZA (D/C/F/TAF), a complete darunavir-based single-tablet regimen for the treatment of HIV-1 infection.   

      A New Drug Application was submitted to the FDA for esketamine nasal spray, a rapidly acting antidepressant for treatment-resistant depression in adults and erdafitinib, a once-daily, oral pan-fibroblast growth factor receptor (FGFR) inhibitor for the treatment of locally advanced or metastatic urothelial cancer. A supplemental New Drug Application was submitted to the FDA seeking to broaden the use of IMBRUVICA (ibrutinib) in chronic lymphocytic leukemia or small lymphocytic lymphoma to include combination use with a non-chemotherapy agent, obinutuzumab, in the frontline setting.  A Type II Variation was submitted to the European Medicines Agency (EMA) seeking to expand the indication of OPSUMIT (macitentan) to include the treatment of adults with inoperable chronic thromboembolic pulmonary hypertension (CTEPH), WHO Group 4, to improve exercise capacity and pulmonary vascular resistance. In addition, the Company also submitted a supplemental Biologics License Application to the FDA and a Type II Variation to the EMA seeking approval of a split dosing regimen for DARZALEX (daratumumab).

      Subsequent to the quarter, the FDA approved an additional indication for XARELTO (rivaroxaban) to reduce the risk of major cardiovascular (CV) events, such as CV death, myocardial infarction and stroke, in people with chronic coronary or peripheral artery disease. Additionally, a Marketing Authorization Application was submitted to the EMA for esketamine nasal spray, a rapidly acting antidepressant for treatment-resistant depression in adults.  The Company also entered into an exclusive worldwide license agreement with Arrowhead Pharmaceuticals, Inc. to develop and commercialize a new treatment for chronic Hepatitis B viral infection. 

      Worldwide Medical Devices sales of $6.6 billion for the third quarter 2018 represented a decrease of 0.2% versus the prior year consisting of an operational increase of 1.7% and a negative currency impact of 1.9%. Domestic sales increased 0.3%, while international sales decreased 0.6%, which reflected an operational increase of 3.0% and a negative currency impact of 3.6%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 2.9%, domestic sales increased 1.2% and international sales increased 4.4%.*

      Worldwide operational results, excluding the net impact of acquisitions and divestitures, were driven by the growth of electrophysiology products in the Interventional Solutions business; ACUVUE contact lenses in the Vision business; endocutters and biosurgicals in the Advanced Surgery business; and wound closure products in the General Surgery business, partially offset by declines in the Diabetes Care business.

      During the quarter, the Company received European CE mark approval for its BRAVO Flow Diverter for use in the treatment of patients suffering from intracranial aneurysms.  In addition, the acquisition of Emerging Implant Technologies GmbH, a privately held manufacturer of 3D-printed titanium interbody implants for spinal fusion surgery, was completed. Lastly, the Company accepted the binding offer from Fortive Corporation to acquire its Advanced Sterilization Products business for an aggregate value of approximately $2.8 billion, subject to customary adjustments.

      Subsequent to the quarter, the Company announced the completion of the divestiture of its LifeScan business to Platinum Equity for approximately $2.1 billion, subject to customary adjustments.

      About Johnson & Johnson
      At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That's why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world's largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.

      * Operational sales growth excluding the net impact of acquisitions and divestitures, as well as adjusted net earnings, adjusted diluted earnings per share and operational adjusted diluted earnings per share excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company's website at www.investor.jnj.com. Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.

      Johnson & Johnson will conduct a conference call with investors to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com. 

      Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, a pharmaceutical pipeline of selected compounds in late stage development and a copy of today's earnings call presentation can be found on the company's website at www.investor.jnj.com.

      NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS

      This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including unexpected clinical trial results, additional analysis of existing clinical data, uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; the impact of business combinations and divestitures; challenges to patents; the impact of patent expirations; the ability of the company to successfully execute strategic plans, including restructuring plans; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws, global health care reforms and import/export and trade laws; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 31, 2017, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," in the company's most recently filed Quarterly Report on Form 10-Q and in the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

      Johnson & Johnson and Subsidiaries




















      Supplementary Sales Data








































      (Unaudited; Dollars in Millions)

      THIRD QUARTER


      NINE MONTHS






      Percent Change






      Percent Change


      2018


      2017


      Total


      Operations


      Currency


      2018


      2017


      Total


      Operations


      Currency

      Sales to customers by




















      segment of business








































      Consumer




















          U.S.

      $   1,370


      1,285


      6.6

      %

      6.6


      -


      $   4,282


      4,186


      2.3

      %

      2.3


      -

          International

      2,045


      2,071


      (1.3)


      3.7


      (5.0)


      6,035


      5,876


      2.7


      1.6


      1.1


      3,415


      3,356


      1.8


      4.9


      (3.1)


      10,317


      10,062


      2.5


      1.9


      0.6





















      Pharmaceutical




















          U.S.

      6,097


      5,816


      4.8


      4.8


      -


      17,350


      15,698


      10.5


      10.5


      -

          International

      4,249


      3,879


      9.5


      13.2


      (3.7)


      13,194


      10,877


      21.3


      17.5


      3.8


      10,346


      9,695


      6.7


      8.2


      (1.5)


      30,544


      26,575


      14.9


      13.4


      1.5





















      Medical Devices




















          U.S.

      3,197


      3,189


      0.3


      0.3


      -


      9,623


      9,510


      1.2


      1.2


      -

          International

      3,390


      3,410


      (0.6)


      3.0


      (3.6)


      10,703


      10,108


      5.9


      3.2


      2.7


      6,587


      6,599


      (0.2)


      1.7


      (1.9)


      20,326


      19,618


      3.6


      2.2


      1.4





















      U.S.

      10,664


      10,290


      3.6


      3.6


      -


      31,255


      29,394


      6.3


      6.3


      -

      International

      9,684


      9,360


      3.5


      7.5


      (4.0)


      29,932


      26,861


      11.4


      8.6


      2.8

      Worldwide

      $ 20,348


      19,650


      3.6

      %

      5.5


      (1.9)


      $ 61,187


      56,255


      8.8

      %

      7.5


      1.3

      Johnson & Johnson and Subsidiaries




















      Supplementary Sales Data








































      (Unaudited; Dollars in Millions)

      THIRD QUARTER


      NINE MONTHS






      Percent Change






      Percent Change


      2018


      2017


      Total


      Operations


      Currency


      2018


      2017


      Total


      Operations


      Currency

      Sales to customers by




















      geographic area








































      U.S.

      $ 10,664


      10,290


      3.6

      %

      3.6


      -


      $ 31,255


      29,394


      6.3

      %

      6.3


      -





















      Europe

      4,416


      4,308


      2.5


      5.1


      (2.6)


      14,023


      12,398


      13.1


      7.1


      6.0

      Western Hemisphere excluding U.S.

      1,550


      1,569


      (1.2)


      11.2


      (12.4)


      4,657


      4,522


      3.0


      8.4


      (5.4)

      Asia-Pacific, Africa

      3,718


      3,483


      6.7


      8.6


      (1.9)


      11,252


      9,941


      13.2


      10.8


      2.4

      International

      9,684


      9,360


      3.5


      7.5


      (4.0)


      29,932


      26,861


      11.4


      8.6


      2.8





















      Worldwide

      $ 20,348


      19,650


      3.6

      %

      5.5


      (1.9)


      $ 61,187


      56,255


      8.8

      %

      7.5


      1.3

      Johnson & Johnson and Subsidiaries










      Condensed Consolidated Statement of Earnings 




















      (Unaudited; in Millions Except Per Share Figures)

      THIRD QUARTER












      2018


      2017*


      Percent




      Percent




      Percent


      Increase


      Amount


      to Sales


      Amount


      to Sales


      (Decrease)

      Sales to customers

      $ 20,348


      100.0


      $ 19,650


      100.0


      3.6

      Cost of products sold

      6,589


      32.4


      6,925


      35.2


      (4.9)

      Gross Profit

      13,759


      67.6


      12,725


      64.8


      8.1

      Selling, marketing and administrative expenses

      5,543


      27.3


      5,423


      27.6


      2.2

      Research and development expense

      2,508


      12.3


      2,585


      13.2


      (3.0)

      In-process research and development

      1,126


      5.6


      -


      -



      Interest (income) expense, net

      68


      0.3


      155


      0.8



      Other (income) expense, net

      3


      0.0


      (297)


      (1.5)



      Restructuring

      88


      0.4


      69


      0.3



      Earnings before provision for taxes on income

      4,423


      21.7


      4,790


      24.4


      (7.7)

      Provision for taxes on income

      489


      2.4


      1,026


      5.2


      (52.3)

      Net earnings

      $   3,934


      19.3


      $   3,764


      19.2


      4.5











      Net earnings per share (Diluted)

      $     1.44




      $     1.37




      5.1











      Average shares outstanding (Diluted)

      2,727.6




      2,737.7















      Effective tax rate

      11.1

      %



      21.4

      %














      Adjusted earnings before provision for taxes and net earnings (1)










      Earnings before provision for taxes on income

      $   6,780


      33.3


      $   6,573


      33.5


      3.1

      Net earnings

      $   5,590


      27.5


      $   5,208


      26.5


      7.3

      Net earnings per share (Diluted)

      $     2.05




      $     1.90




      7.9

      Effective tax rate

      17.6

      %



      20.8

      %














      (1)See Reconciliation of Non-GAAP Financial Measures.




















      *2017 Statement of Earnings line items have been restated to reflect impact of ASU 2017-07

      Johnson & Johnson and Subsidiaries










      Condensed Consolidated Statement of Earnings 




















      (Unaudited; in Millions Except Per Share Figures)

      NINE MONTHS












      2018


      2017*


      Percent




      Percent




      Percent


      Increase


      Amount


      to Sales


      Amount


      to Sales


      (Decrease)

      Sales to customers

      $ 61,187


      100.0


      $ 56,255


      100.0


      8.8

      Cost of products sold

      20,130


      32.9


      18,180


      32.3


      10.7

      Gross Profit

      41,057


      67.1


      38,075


      67.7


      7.8

      Selling, marketing and administrative expenses

      16,549


      27.1


      15,475


      27.5


      6.9

      Research and development expense

      7,551


      12.3


      6,951


      12.4


      8.6

      In-process research and development

      1,126


      1.8


      -


      -



      Interest (income) expense, net

      340


      0.6


      360


      0.6



      Other (income) expense, net

      427


      0.7


      11


      0.0



      Restructuring

      187


      0.3


      165


      0.3



      Earnings before provision for taxes on income

      14,877


      24.3


      15,113


      26.9


      (1.6)

      Provision for taxes on income

      2,622


      4.3


      3,100


      5.5


      (15.4)

      Net earnings

      $ 12,255


      20.0


      $ 12,013


      21.4


      2.0











      Net earnings per share (Diluted)

      $     4.49




      $     4.37




      2.7











      Average shares outstanding (Diluted)

      2,729.6




      2,746.4















      Effective tax rate

      17.6

      %



      20.5

      %














      Adjusted earnings before provision for taxes and net earnings (1)










      Earnings before provision for taxes on income

      $ 20,652


      33.8


      $ 18,961


      33.7


      8.9

      Net earnings

      $ 16,943


      27.7


      $ 15,263


      27.1


      11.0

      Net earnings per share (Diluted)

      $     6.21




      $     5.56




      11.7

      Effective tax rate

      18.0

      %



      19.5

      %














      (1)See Reconciliation of Non-GAAP Financial Measures.




















      *2017 Statement of Earnings line items have been restated to reflect impact of ASU 2017-07

      Johnson & Johnson and Subsidiaries















      Reconciliation of Non-GAAP Financial Measures
































      Third Quarter


      % Incr. /



      Nine Months YTD


      % Incr. /


      (Dollars in Millions Except Per Share Data)


      2018


      2017


      (Decr.)



      2018


      2017


      (Decr.)

















      Earnings before provision for taxes on income - as reported


      $      4,423


      4,790


      (7.7)

      %


      $    14,877


      15,113


      (1.6)

      %

      Intangible asset amortization expense


      1,085


      1,077





      3,284


      1,886




      In-process research and development


      1,126


      -





      1,126


      -




      Litigation expense, net


      -


      118





      703


      611




      Restructuring/Other (1)


      190


      187





      473


      476




      Actelion acquisition related cost


      40


      367





      200


      580




      Contingent liability reversal


      (184)


      -





      (184)


      -




      AMO acquisition related cost


      36


      36





      82


      115




      Diabetes asset impairment


      -


      (2)





      4


      180




      Unrealized loss/(gain) on securities


      9


      -





      (3)


      -




      Other


      55


      -





      90


      -



















      Earnings before provision for taxes on income - as adjusted


      $      6,780


      6,573


      3.1

      %


      $    20,652


      18,961


      8.9

      %
















      Net Earnings - as reported


      $      3,934


      3,764


      4.5

      %


      $    12,255


      12,013


      2.0

      %

      Intangible asset amortization expense


      968


      933





      2,931


      1,555




      In-process research and development


      859


      -





      859


      -




      Litigation expense, net


      -


      97





      609


      449




      Restructuring/Other


      162


      136





      395


      358




      Actelion acquisition related cost


      37


      255





      193


      454




      Contingent liability reversal


      (184)


      -





      (184)


      -




      AMO acquisition related cost


      29


      28





      68


      314




      Diabetes asset impairment


      -


      (5)





      3


      120




      Unrealized loss/(gain) on securities


      8


      -





      (2)


      -




      Impact of tax legislation (2)


      (265)


      -





      (253)


      -




      Other


      42


      -





      69


      -



















      Net Earnings - as adjusted 


      $      5,590


      5,208


      7.3

      %


      $    16,943


      15,263


      11.0

      %
















      Diluted Net Earnings per share - as reported


      $        1.44


      1.37


      5.1

      %


      $        4.49


      4.37


      2.7

      %

      Intangible asset amortization expense


      0.35


      0.34





      1.07


      0.57




      In-process research and development


      0.32


      -





      0.32


      -




      Litigation expense, net


      -


      0.04





      0.22


      0.16




      Restructuring/Other


      0.06


      0.05





      0.15


      0.14




      Actelion acquisition related cost


      0.02


      0.09





      0.07


      0.16




      Contingent liability reversal


      (0.07)


      -





      (0.07)


      -




      AMO acquisition related cost


      0.01


      0.01





      0.02


      0.11




      Diabetes asset impairment


      -


      -





      -


      0.05




      Unrealized loss/(gain) on securities


      -


      -





      -


      -




      Impact of tax legislation


      (0.10)


      -





      (0.09)


      -




      Other


      0.02


      -





      0.03


      -



















      Diluted Net Earnings per share - as adjusted 


      $        2.05


      1.90


      7.9

      %


      $        6.21


      5.56


      11.7

      %
















      Operational Diluted Net Earnings per share - as adjusted 















      at 2016 foreign currency exchange rates




      1.85







      5.57



















      Impact of currency at 2017 foreign currency exchange rates


      0.03


      0.05





      (0.17)


      (0.01)



















      Operational Diluted Net Earnings per share - as adjusted 















      at 2017 foreign currency exchange rates


      $        2.08


      1.90


      9.5

      %


      $        6.04


      5.56


      8.6

      %
















      (1)Includes $23M recorded in cost of products sold and $79M recorded in other (income) expense for the third quarter 2018. Includes $73M recorded in cost of products sold




      and $213M recorded in other (income) expense for nine months 2018 YTD.  Includes $29M recorded in cost of products sold and $89M recorded in other (income) expense for the 



      third quarter 2017.  Includes $46M recorded in cost of products sold and $265M recorded in other (income) expense for nine months 2017 YTD.






















      (2)Includes foreign currency translation















      Johnson & Johnson and Subsidiaries









      Reconciliation of Non-GAAP Financial Measure


















      Operational Sales Growth Excluding Acquisitions and Divestitures

       THIRD QUARTER 2018 ACTUAL vs. 2017 ACTUAL 











       Segments 



       Consumer 


       Pharmaceutical 


       Medical Devices 


       Total 



      Operational % (1)

       WW As Reported: 


      4.9%


      8.2%


      1.7%


      5.5%

       U.S. 


      6.6%


      4.8%


      0.3%


      3.6%

       International 


      3.7%


      13.2%


      3.0%


      7.5%



















      Spine & Other 









      Codman Neuroscience






      1.0


      0.4

       U.S. 






      0.6


      0.2

       International 






      1.4


      0.5










      Wound Care / Other









      Compeed


      0.8






      0.1

       U.S. 


      0.0






      0.0

       International 


      1.3






      0.3










      Beauty









      Nizoral


      0.5






      0.1

       U.S. 


      0.3






      0.0

       International 


      0.7






      0.1










      All Other Acquisitions and Divestitures


      (0.1)


      0.0


      0.2


      0.0

       U.S. 


      (0.5)


      0.0


      0.3


      0.1

       International 


      0.2


      0.0


      0.0


      0.1










      WW Ops excluding Acquisitions and Divestitures


      6.1%


      8.2%


      2.9%


      6.1%

       U.S. 


      6.4%


      4.8%


      1.2%


      3.9%

       International 


      5.9%


      13.2%


      4.4%


      8.5%










      (1)Operational growth excludes the effect of translational currency









      Johnson & Johnson and Subsidiaries









      Reconciliation of Non-GAAP Financial Measure


















      Operational Sales Growth Excluding Acquisitions and Divestitures

       NINE MONTHS 2018 ACTUAL vs. 2017 ACTUAL 










       Segments 



       Consumer 


       Pharmaceutical 


       Medical Devices 


       Total 



      Operational % (1)

       WW As Reported: 


      1.9%


      13.4%


      2.2%


      7.5%

       U.S. 


      2.3%


      10.5%


      1.2%


      6.3%

       International 


      1.6%


      17.5%


      3.2%


      8.6%










      Pulmonary Hypertension









      Actelion




      (4.3)




      (2.0)

       U.S. 




      (4.7)




      (2.5)

       International 




      (3.8)




      (1.6)










      Cardiovascular / Metabolism / Other









      Actelion




      (0.2)




      (0.1)

       U.S. 




      (0.1)




      (0.1)

       International 




      (0.3)




      (0.1)










      Spine & Other 









      Codman Neuroscience






      1.0


      0.4

       U.S. 






      0.6


      0.3

       International 






      1.4


      0.6










      Wound Care / Other









      Compeed


      0.9






      0.2

       U.S. 


      0.0






      0.0

       International 


      1.5






      0.3










      Vision









      Vision Surgical & Eye Health Business






      (1.0)


      (0.4)

        U.S.  






      (0.9)


      (0.3)

        International  






      (1.1)


      (0.4)










      Beauty









      Nizoral


      0.2






      0.0

        U.S.  


      0.1






      0.0

        International  


      0.3






      0.1










      All Other Acquisitions and Divestitures


      0.0


      0.0


      0.1


      0.0

       U.S. 


      (0.1)


      0.0


      0.0


      0.0

       International 


      0.2


      0.0


      0.2


      0.1










      WW Ops excluding Acquisitions and Divestitures


      3.0%


      8.9%


      2.3%


      5.6%

       U.S. 


      2.3%


      5.7%


      0.9%


      3.7%

       International 


      3.6%


      13.4%


      3.7%


      7.6%










      (1)Operational growth excludes the effect of translational currency












      REPORTED SALES vs. PRIOR PERIOD ($MM)



      THIRD QUARTER


      NINE MONTHS







      % Change






      % Change




      2018


      2017

      Reported

      Operational (1)

      Currency



      2018


      2017

      Reported

      Operational (1)

      Currency


      CONSUMER SEGMENT (2) 

















      BABY CARE

















      US


      $         120


      $             100

      20.0%

      20.0%

      -



      $               306


      $               326

      -6.1%

      -6.1%

      -


      Intl


      352


      377

      -6.6%

      0.1%

      -6.7%



      1,079


      1,100

      -1.9%

      -0.5%

      -1.4%


      WW


      472


      477

      -1.0%

      4.3%

      -5.3%



      1,385


      1,426

      -2.9%

      -1.8%

      -1.1%


      BEAUTY

















      US


      543


      523

      3.8%

      3.8%

      -



      1,791


      1,739

      3.0%

      3.0%

      -


      Intl


      535


      510

      4.9%

      9.2%

      -4.3%



      1,480


      1,351

      9.5%

      7.7%

      1.8%


      WW


      1,078


      1,033

      4.4%

      6.5%

      -2.1%



      3,271


      3,090

      5.9%

      5.1%

      0.8%


      ORAL CARE

















      US


      158


      154

      2.6%

      2.6%

      -



      472


      460

      2.6%

      2.6%

      -


      Intl


      226


      228

      -0.9%

      3.6%

      -4.5%



      684


      678

      0.9%

      -0.5%

      1.4%


      WW


      384


      382

      0.5%

      3.2%

      -2.7%



      1,156


      1,138

      1.6%

      0.7%

      0.9%


      OTC
















      US


      440


      401

      9.7%

      9.7%

      -



      1,359


      1,310

      3.7%

      3.7%

      -


      Intl


      608


      601

      1.2%

      4.8%

      -3.6%



      1,827


      1,711

      6.8%

      3.8%

      3.0%


      WW


      1,048


      1,002

      4.6%

      6.8%

      -2.2%



      3,186


      3,021

      5.5%

      3.8%

      1.7%


      WOMEN'S HEALTH

















      US


      3


      3

      0.0%

      0.0%

      -



      10


      9

      11.1%

      11.1%

      -


      Intl


      266


      267

      -0.4%

      8.0%

      -8.4%



      782


      779

      0.4%

      2.0%

      -1.6%


      WW


      269


      270

      -0.4%

      7.9%

      -8.3%



      792


      788

      0.5%

      2.1%

      -1.6%


      WOUND CARE / OTHER

















      US


      106


      104

      1.9%

      1.9%

      -



      344


      342

      0.6%

      0.6%

      -


      Intl


      58


      88

      -34.1%

      -31.3%

      -2.8%



      183


      257

      -28.8%

      -30.0%

      1.2%


      WW


      164


      192

      -14.6%

      -13.3%

      -1.3%



      527


      599

      -12.0%

      -12.5%

      0.5%



















      TOTAL CONSUMER

















      US


      1,370


      1,285

      6.6%

      6.6%

      -



      4,282


      4,186

      2.3%

      2.3%

      -


      Intl


      2,045


      2,071

      -1.3%

      3.7%

      -5.0%



      6,035


      5,876

      2.7%

      1.6%

      1.1%


      WW


      $      3,415


      $          3,356

      1.8%

      4.9%

      -3.1%



      $          10,317


      $          10,062

      2.5%

      1.9%

      0.6%




























      See footnotes at end of schedule



















      REPORTED SALES vs. PRIOR PERIOD ($MM)





      THIRD QUARTER


      NINE MONTHS









      % Change






      % Change






      2018


      2017

      Reported

      Operational (1)

      Currency



      2018


      2017

      Reported

      Operational (1)

      Currency




      PHARMACEUTICAL SEGMENT (2)(5)



















      IMMUNOLOGY



















      US


      $      2,400


      $          2,420

      -0.8%

      -0.8%

      -



      $            6,717


      $            6,644

      1.1%

      1.1%

      -




      Intl


      998


      849

      17.6%

      21.7%

      -4.1%



      3,061


      2,514

      21.8%

      18.6%

      3.2%




      WW


      3,398


      3,269

      3.9%

      5.0%

      -1.1%



      9,778


      9,158

      6.8%

      5.9%

      0.9%




      REMICADE



















      US 


      987


      1,206

      -18.2%

      -18.2%

      -



      2,821


      3,452

      -18.3%

      -18.3%

      -




      US Exports (3)


      100


      156

      -35.9%

      -35.9%

      -



      346


      448

      -22.8%

      -22.8%

      -




      Intl


      292


      285

      2.5%

      8.2%

      -5.7%



      921


      949

      -3.0%

      -3.9%

      0.9%




      WW


      1,379


      1,647

      -16.3%

      -15.3%

      -1.0%



      4,088


      4,849

      -15.7%

      -15.9%

      0.2%




      SIMPONI / SIMPONI ARIA



















      US


      281


      242

      16.1%

      16.1%

      -



      779


      701

      11.1%

      11.1%

      -




      Intl


      255


      234

      9.0%

      13.5%

      -4.5%



      823


      642

      28.2%

      25.3%

      2.9%




      WW


      536


      476

      12.6%

      14.8%

      -2.2%



      1,602


      1,343

      19.3%

      17.9%

      1.4%




      STELARA



















      US


      889


      800

      11.1%

      11.1%

      -



      2,460


      2,027

      21.4%

      21.4%

      -




      Intl


      421


      324

      29.9%

      33.0%

      -3.1%



      1,252


      903

      38.6%

      32.9%

      5.7%




      WW


      1,310


      1,124

      16.5%

      17.4%

      -0.9%



      3,712


      2,930

      26.7%

      24.9%

      1.8%




      OTHER IMMUNOLOGY



















      US


      143


      16

      *

      *

      -



      311


      16

      *

      *

      -




      Intl


      30


      6

      *

      *

      *



      65


      20

      *

      *

      *




      WW


      173


      22

      *

      *

      *



      376


      36

      *

      *

      *




      INFECTIOUS DISEASES



















      US


      345


      353

      -2.3%

      -2.3%

      -



      1,006


      1,020

      -1.4%

      -1.4%

      -




      Intl


      478


      460

      3.9%

      7.4%

      -3.5%



      1,496


      1,334

      12.1%

      8.1%

      4.0%




      WW


      823


      813

      1.2%

      3.2%

      -2.0%



      2,502


      2,354

      6.3%

      4.0%

      2.3%




      EDURANT / rilpivirine



















      US


      13


      15

      -13.3%

      -13.3%

      -



      42


      44

      -4.5%

      -4.5%

      -




      Intl


      189


      179

      5.6%

      6.8%

      -1.2%



      581


      478

      21.5%

      14.2%

      7.3%




      WW


      202


      194

      4.1%

      5.2%

      -1.1%



      623


      522

      19.3%

      12.6%

      6.7%




      PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA



















      US


      297


      287

      3.5%

      3.5%

      -



      847


      824

      2.8%

      2.8%

      -




      Intl


      193


      180

      7.2%

      12.4%

      -5.2%



      613


      527

      16.3%

      13.5%

      2.8%




      WW


      490


      467

      4.9%

      6.9%

      -2.0%



      1,460


      1,351

      8.1%

      7.0%

      1.1%




      OTHER INFECTIOUS DISEASES



















      US


      35


      51

      -31.4%

      -31.4%

      -



      117


      152

      -23.0%

      -23.0%

      -




      Intl


      96


      101

      -5.0%

      -0.3%

      -4.7%



      302


      329

      -8.2%

      -9.3%

      1.1%




      WW


      131


      152

      -13.8%

      -10.7%

      -3.1%



      419


      481

      -12.9%

      -13.7%

      0.8%


















      REPORTED SALES vs. PRIOR PERIOD ($MM)





      THIRD QUARTER


      NINE MONTHS









      % Change






      % Change






      2018


      2017

      Reported

      Operational (1)

      Currency



      2018


      2017

      Reported

      Operational (1)

      Currency




      NEUROSCIENCE



















      US


      651


      647

      0.6%

      0.6%

      -



      1,914


      1,931

      -0.9%

      -0.9%

      -




      Intl


      839


      851

      -1.4%

      2.1%

      -3.5%



      2,663


      2,531

      5.2%

      2.3%

      2.9%




      WW


      1,490


      1,498

      -0.5%

      1.5%

      -2.0%



      4,577


      4,462

      2.6%

      0.9%

      1.7%




      CONCERTA / methlyphenidate



















      US


      57


      100

      -43.0%

      -43.0%

      -



      191


      284

      -32.7%

      -32.7%

      -




      Intl


      100


      98

      2.0%

      7.3%

      -5.3%



      322


      304

      5.9%

      4.4%

      1.5%




      WW


      157


      198

      -20.7%

      -18.1%

      -2.6%



      513


      588

      -12.8%

      -13.6%

      0.8%




      INVEGA SUSTENNA / XEPLION / TRINZA / TREVICTA



















      US


      468


      395

      18.5%

      18.5%

      -



      1,306


      1,154

      13.2%

      13.2%

      -




      Intl


      281


      248

      13.3%

      16.6%

      -3.3%



      859


      722

      19.0%

      14.2%

      4.8%




      WW


      749


      643

      16.5%

      17.8%

      -1.3%



      2,165


      1,876

      15.4%

      13.5%

      1.9%




      RISPERDAL CONSTA



















      US


      76


      87

      -12.6%

      -12.6%

      -



      238


      273

      -12.8%

      -12.8%

      -




      Intl


      99


      107

      -7.5%

      -4.0%

      -3.5%



      321


      335

      -4.2%

      -7.3%

      3.1%




      WW


      175


      194

      -9.8%

      -7.9%

      -1.9%



      559


      608

      -8.1%

      -9.8%

      1.7%




      OTHER NEUROSCIENCE



















      US


      50


      65

      -23.1%

      -23.1%

      -



      179


      220

      -18.6%

      -18.6%

      -




      Intl


      359


      398

      -9.8%

      -6.6%

      -3.2%



      1,161


      1,170

      -0.8%

      -2.9%

      2.1%




      WW


      409


      463

      -11.7%

      -9.0%

      -2.7%



      1,340


      1,390

      -3.6%

      -5.4%

      1.8%




      ONCOLOGY



















      US


      1,250


      846

      47.8%

      47.8%

      -



      3,268


      2,207

      48.1%

      48.1%

      -




      Intl


      1,338


      1,052

      27.2%

      31.2%

      -4.0%



      4,087


      3,012

      35.7%

      30.9%

      4.8%




      WW


      2,588


      1,898

      36.4%

      38.6%

      -2.2%



      7,355


      5,219

      40.9%

      38.1%

      2.8%




      DARZALEX



















      US


      318


      230

      38.3%

      38.3%

      -



      880


      643

      36.9%

      36.9%

      -




      Intl


      180


      87

      *

      *

      *



      561


      228

      *

      *

      *




      WW


      498


      317

      57.1%

      60.0%

      -2.9%



      1,441


      871

      65.4%

      63.6%

      1.8%




      IMBRUVICA



















      US


      334


      230

      45.2%

      45.2%

      -



      811


      622

      30.4%

      30.4%

      -




      Intl


      371


      282

      31.6%

      36.6%

      -5.0%



      1,101


      749

      47.0%

      42.2%

      4.8%




      WW


      705


      512

      37.7%

      40.4%

      -2.7%



      1,912


      1,371

      39.5%

      36.9%

      2.6%




      VELCADE



















      US


      -


      -

      -

      -

      -



      -


      -

      -

      -

      -




      Intl


      271


      273

      -0.7%

      1.8%

      -2.5%



      864


      843

      2.5%

      -1.7%

      4.2%




      WW


      271


      273

      -0.7%

      1.8%

      -2.5%



      864


      843

      2.5%

      -1.7%

      4.2%




      ZYTIGA



















      US


      527


      352

      49.7%

      49.7%

      -



      1,420


      826

      71.9%

      71.9%

      -




      Intl


      431


      317

      36.0%

      38.8%

      -2.8%



      1,292


      924

      39.8%

      34.2%

      5.6%




      WW


      958


      669

      43.2%

      44.5%

      -1.3%



      2,712


      1,750

      55.0%

      52.0%

      3.0%




      OTHER ONCOLOGY



















      US


      71


      34

      *

      *

      -



      157


      116

      35.3%

      35.3%

      -




      Intl


      85


      93

      -8.6%

      -4.7%

      -3.9%



      269


      268

      0.4%

      -2.5%

      2.9%




      WW


      156


      127

      22.8%

      25.6%

      -2.8%



      426


      384

      10.9%

      8.9%

      2.0%




      PULMONARY HYPERTENSION(4)



















      US


      425


      371

      14.6%

      14.6%

      -



      1,215


      408

      *

      *

      -




      Intl


      231


      261

      -11.5%

      -8.9%

      -2.6%



      691


      309

      *

      *

       * 




      WW


      656


      632

      3.8%

      4.9%

      -1.1%



      1,906


      717

      *

      *

       * 




      OPSUMIT



















      US


      182


      150

      21.3%

      21.3%

      -



      511


      174

      *

      *

      -




      Intl


      128


      109

      17.4%

      20.9%

      -3.5%



      381


      130

      *

      *

       * 




      WW


      310


      259

      19.7%

      21.2%

      -1.5%



      892


      304

      *

      *

       * 




      TRACLEER



















      US


      69


      83

      -16.9%

      -16.9%

      -



      208


      85

      *

      *

      -




      Intl


      70


      127

      -44.9%

      -43.6%

      -1.3%



      214


      151

      41.7%

      37.5%

      4.2%




      WW


      139


      210

      -33.8%

      -33.0%

      -0.8%



      422


      236

      78.8%

      76.1%

      2.7%




      UPTRAVI



















      US


      154


      113

      36.3%

      36.3%

      -



      433


      121

      *

      *

      -




      Intl


      17


      11

      54.5%

      57.3%

      -2.8%



      49


      12

      *

      *

       * 




      WW


      171


      124

      37.9%

      38.1%

      -0.2%



      482


      133

      *

      *

       * 




      OTHER



















      US


      20


      25

      -20.0%

      -20.0%

      -



      63


      28

      *

      *

      -




      Intl


      16


      14

      14.3%

      21.2%

      -6.9%



      47


      16

      *

      *

       * 




      WW


      36


      39

      -7.7%

      -5.2%

      -2.5%



      110


      44

      *

      *

       * 




      CARDIOVASCULAR / METABOLISM / OTHER



















      US


      1,026


      1,179

      -13.0%

      -13.0%

      -



      3,230


      3,488

      -7.4%

      -7.4%

      -




      Intl


      365


      406

      -10.1%

      -6.5%

      -3.6%



      1,196


      1,177

      1.6%

      -1.1%

      2.7%




      WW


      1,391


      1,585

      -12.2%

      -11.3%

      -0.9%



      4,426


      4,665

      -5.1%

      -5.8%

      0.7%




      XARELTO



















      US


      612


      635

      -3.6%

      -3.6%

      -



      1,869


      1,790

      4.4%

      4.4%

      -




      Intl


      -


      -

      -

      -

      -



      -


      -

      -

      -

      -




      WW


      612


      635

      -3.6%

      -3.6%

      -



      1,869


      1,790

      4.4%

      4.4%

      -




      INVOKANA / INVOKAMET



















      US


      150


      220

      -31.8%

      -31.8%

      -



      523


      723

      -27.7%

      -27.7%

      -




      Intl


      40


      45

      -11.1%

      -6.7%

      -4.4%



      130


      121

      7.4%

      4.8%

      2.6%




      WW


      190


      265

      -28.3%

      -27.6%

      -0.7%



      653


      844

      -22.6%

      -23.0%

      0.4%




      PROCRIT / EPREX



















      US


      178


      168

      6.0%

      6.0%

      -



      523


      511

      2.3%

      2.3%

      -




      Intl


      77


      70

      10.0%

      12.8%

      -2.8%



      244


      229

      6.6%

      2.9%

      3.7%




      WW


      255


      238

      7.1%

      7.9%

      -0.8%



      767


      740

      3.6%

      2.4%

      1.2%




      OTHER



















      US


      86


      156

      -44.9%

      -44.9%

      -



      315


      464

      -32.1%

      -32.1%

      -




      Intl


      248


      291

      -14.8%

      -11.1%

      -3.7%



      822


      827

      -0.6%

      -3.1%

      2.5%




      WW


      334


      447

      -25.3%

      -22.9%

      -2.4%



      1,137


      1,291

      -11.9%

      -13.5%

      1.6%




      TOTAL PHARMACEUTICAL



















      US


      6,097


      5,816

      4.8%

      4.8%

      -



      17,350


      15,698

      10.5%

      10.5%

      -




      Intl


      4,249


      3,879

      9.5%

      13.2%

      -3.7%



      13,194


      10,877

      21.3%

      17.5%

      3.8%




      WW


      $    10,346


      $          9,695

      6.7%

      8.2%

      -1.5%



      $          30,544


      $          26,575

      14.9%

      13.4%

      1.5%


















      See footnotes at end of schedule
















      REPORTED SALES vs. PRIOR PERIOD ($MM)



      THIRD QUARTER


      NINE MONTHS







      % Change






      % Change




      2018


      2017

      Reported

      Operational (1)

      Currency



      2018


      2017

      Reported

      Operational (1)

      Currency


      MEDICAL DEVICES SEGMENT (2)(5)

















      DIABETES CARE

















      US


      $         125


      $             168

      -25.6%

      -25.6%

      -



      $               371


      $               482

      -23.0%

      -23.0%

      -


      Intl


      190


      237

      -19.8%

      -16.0%

      -3.8%



      638


      743

      -14.1%

      -16.3%

      2.2%


      WW


      315


      405

      -22.2%

      -20.0%

      -2.2%



      1,009


      1,225

      -17.6%

      -19.0%

      1.4%


      DIAGNOSTICS

















      US


      -


      -

      -

      -

      -



      -


      -

      -

      -

      -


      Intl


      -


      -

      -

      -

      -



      -


      1

      *

      *

      *


      WW


      -


      -

      -

      -

      -



      -


      1

      *

      *

      *


      INTERVENTIONAL SOLUTIONS

















      US


      320


      279

      14.7%

      14.7%

      0.0%



      947


      843

      12.3%

      12.3%

      -


      Intl


      333


      274

      21.5%

      24.1%

      -2.6%



      1,013


      832

      21.8%

      17.5%

      4.3%


      WW


      653


      553

      18.1%

      19.4%

      -1.3%



      1,960


      1,675

      17.0%

      14.9%

      2.1%


      ORTHOPAEDICS

















      US 


      1,284


      1,308

      -1.8%

      -1.8%

      -



      3,923


      4,034

      -2.8%

      -2.8%

      -


      Intl


      827


      896

      -7.7%

      -4.4%

      -3.3%



      2,700


      2,738

      -1.4%

      -4.6%

      3.2%


      WW


      2,111


      2,204

      -4.2%

      -2.9%

      -1.3%



      6,623


      6,772

      -2.2%

      -3.5%

      1.3%


      HIPS

















      US


      201


      195

      3.1%

      3.1%

      -



      621


      612

      1.5%

      1.5%

      -


      Intl


      129


      133

      -3.0%

      1.0%

      -4.0%



      432


      418

      3.3%

      0.1%

      3.2%


      WW


      330


      328

      0.6%

      2.2%

      -1.6%



      1,053


      1,030

      2.2%

      0.9%

      1.3%


      KNEES

















      US


      215


      220

      -2.3%

      -2.3%

      -



      672


      702

      -4.3%

      -4.3%

      -


      Intl


      126


      123

      2.4%

      6.8%

      -4.4%



      438


      424

      3.3%

      0.2%

      3.1%


      WW


      341


      343

      -0.6%

      1.0%

      -1.6%



      1,110


      1,126

      -1.4%

      -2.6%

      1.2%


      TRAUMA

















      US


      395


      398

      -0.8%

      -0.8%

      -



      1,196


      1,179

      1.4%

      1.4%

      -


      Intl


      259


      264

      -1.9%

      1.0%

      -2.9%



      829


      768

      7.9%

      4.4%

      3.5%


      WW


      654


      662

      -1.2%

      0.0%

      -1.2%



      2,025


      1,947

      4.0%

      2.6%

      1.4%


      SPINE & OTHER

















      US


      473


      495

      -4.4%

      -4.4%

      -



      1,434


      1,541

      -6.9%

      -6.9%

      -


      Intl


      313


      376

      -16.8%

      -13.9%

      -2.9%



      1,001


      1,128

      -11.3%

      -14.3%

      3.0%


      WW


      786


      871

      -9.8%

      -8.6%

      -1.2%



      2,435


      2,669

      -8.8%

      -10.1%

      1.3%


      SURGERY

















      US


      1,016


      1,002

      1.4%

      1.4%

      -



      3,031


      3,009

      0.7%

      0.7%

      -


      Intl


      1,360


      1,344

      1.2%

      5.6%

      -4.4%



      4,283


      3,992

      7.3%

      5.0%

      2.3%


      WW


      2,376


      2,346

      1.3%

      3.8%

      -2.5%



      7,314


      7,001

      4.5%

      3.2%

      1.3%


      ADVANCED

















      US


      421


      398

      5.8%

      5.8%

      -



      1,216


      1,190

      2.2%

      2.2%

      -


      Intl


      555


      525

      5.7%

      10.0%

      -4.3%



      1,731


      1,543

      12.2%

      9.5%

      2.7%


      WW


      976


      923

      5.7%

      8.1%

      -2.4%



      2,947


      2,733

      7.8%

      6.3%

      1.5%


      GENERAL

















      US


      423


      430

      -1.6%

      -1.6%

      -



      1,282


      1,276

      0.5%

      0.5%

      -


      Intl


      657


      675

      -2.7%

      1.6%

      -4.3%



      2,094


      2,017

      3.8%

      1.5%

      2.3%


      WW


      1,080


      1,105

      -2.3%

      0.3%

      -2.6%



      3,376


      3,293

      2.5%

      1.1%

      1.4%


      SPECIALTY

















      US


      172


      174

      -1.1%

      -1.1%

      -



      533


      543

      -1.8%

      -1.8%

      -


      Intl


      148


      144

      2.8%

      7.9%

      -5.1%



      458


      432

      6.0%

      4.9%

      1.1%


      WW


      320


      318

      0.6%

      2.9%

      -2.3%



      991


      975

      1.6%

      1.1%

      0.5%


      VISION

















      US


      452


      432

      4.6%

      4.6%

      -



      1,351


      1,142

      18.3%

      18.3%

      -


      Intl


      680


      659

      3.2%

      6.2%

      -3.0%



      2,069


      1,802

      14.8%

      12.6%

      2.2%


      WW


      1,132


      1,091

      3.8%

      5.6%

      -1.8%



      3,420


      2,944

      16.2%

      14.9%

      1.3%


      CONTACT LENSES / OTHER

















      US


      319


      302

      5.6%

      5.6%

      -



      948


      832

      13.9%

      13.9%

      -


      Intl


      516


      498

      3.6%

      6.4%

      -2.8%



      1,538


      1,404

      9.5%

      7.4%

      2.1%


      WW


      835


      800

      4.4%

      6.2%

      -1.8%



      2,486


      2,236

      11.2%

      9.9%

      1.3%


      SURGICAL

















      US


      133


      130

      2.3%

      2.3%

      -



      403


      310

      30.0%

      30.0%

      -


      Intl


      164


      161

      1.9%

      5.5%

      -3.6%



      531


      398

      33.4%

      31.0%

      2.4%


      WW


      297


      291

      2.1%

      4.1%

      -2.0%



      934


      708

      31.9%

      30.5%

      1.4%



















      TOTAL MEDICAL DEVICES

















      US


      3,197


      3,189

      0.3%

      0.3%

      -



      9,623


      9,510

      1.2%

      1.2%

      -


      Intl


      3,390


      3,410

      -0.6%

      3.0%

      -3.6%



      10,703


      10,108

      5.9%

      3.2%

      2.7%


      WW


      $      6,587


      6,599

      -0.2%

      1.7%

      -1.9%



      $          20,326


      $          19,618

      3.6%

      2.2%

      1.4%




































      * Percentage greater than 100% or not meaningful

















      (1) Operational growth excludes the effect of translational currency















      (2) Unaudited

















      (3) Reported as U.S. sales

















      (4) Products acquired from Actelion acquisition on June 16, 2017















      (5) Prior year amounts have been reclassified to conform to current year product disclosure 











      SOURCE Johnson & Johnson

      Modal title

      Also from this source

      Johnson & Johnson Announces CAPLYTA (lumateperone) Shows Significant and Rapid Improvement in Bipolar Mania in Second Pivotal Phase 3 Study

      Johnson & Johnson Announces CAPLYTA (lumateperone) Shows Significant and Rapid Improvement in Bipolar Mania in Second Pivotal Phase 3 Study

      Johnson & Johnson (NYSE: JNJ) today announced that Study 452, the second pivotal Phase 3 study evaluating CAPLYTA (lumateperone) for the treatment of ...

      Johnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancer

      Johnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancer

      Johnson & Johnson (NYSE: JNJ) today announced promising first-in-human Phase 1 results for the investigational combination of pasritamig and...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Conference Call Announcements

      Conference Call Announcements

      Earnings

      Earnings

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.